





FIG. 1A



MC4R Agonist I QW	Plasma ng/mL	CSF ng/mL	BW reduction on day 22 vs Placebo
5 mg	43.8 (6.9)	0.72 (0.03)	-12.9%
10 mg/kg	90.4 (8.8)	1.67 (0.12)	-15.6%

FIG. 1B

3/33




FIG. 2A




FIG. 2B




FIG. 3A

5/33




FIG. 3B

6/33




FIG. 3C




FIG. 4A




FIG. 4B




FIG. 5

10/33




FIG. 6

11/33




FIG. 7A




FIG. 7B

12/33




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D

14/33




FIG. 9A




FIG. 9B

15/33




FIG. 9C





FIG. 9D






FIG. 10C




FIG. 10B




FIG. 10D




FIG. 11




FIG. 12A

21/33




FIG. 12B






FIG. 13



Data are shown as individual data points (n=2-3) and means and SEM are also shown.
denotes scores combined to determine the NAFLD activity score (NAS).
There is insufficient power to achieve statistical significance.

FIG. 14



25/33




FIG. 16A






FIG. 16B





SURx/Kirx Channel Activator I and MC4R Agonist I
Concentrations in Liver, CSF, and Plasma

Test articles		CSF ng/mL	Liver ng/mL	Plasma ng/mL	Liver/ Plasma*	CSF/ Plasma*
Combo arm SURx/Kirx Channel Activator I (100 mg/kg/d) + MC4R Agonist I (5 mg/kg)	(100mg/kg/d)		25,133 ± 2003.9	27,600 ± 1861.9	0.91	0.02
			23,714 ± 2975.1	31,371 ± 2377.1	0.76	0.014
			12.7 ± 1.23	27.6 ± 2.8	0.46	0.02

FIG. 18

30/33




FIG. 19A

31/33




FIG. 19B

32/33




FIG. 19C

33/33




FIG. 19D